|
CXCR4-Targeting Molecules for Tumor Metastasis and PET Imaging
Application
Positron emission tomography (PET) imaging agents with high specificity for metastatic cancer.
Key Benefits
18F-labeled CXCR4 (partial) antagonist without stem cell mobilizing property is safe to be given to patient multiple times.
Identifies tumor location non-invasively and provides an indication of tumor’s metastatic potential.
Market...
Published: 4/23/2024
Contributor(s): Hyunsuk Shim, Mark Goodman, Dinesh Shetty, Yoon Hyeun Oum
|
|
Novel Piperidine-Amide Derivatives as CXCR4 Modulators
Application
A new class of CXCR4 modulators for metastasis and inflammation.
Key Benefits
Selective for only one allosteric site on CXCR4.
Lower adverse effects.
Market Summary
Activation of the CXCR4 receptor triggers multiple signaling pathways that orchestrate cell migration, hematopoiesis and cell homing, and retention in the bone...
Published: 11/27/2023
Contributor(s): Hyunsuk Shim, Yoon Hyeun Oum
|
|
Chimeric Molecule for the Treatment of Depression
Application
Small molecules for treating depression and/or depression associated with cancer/chemotherapy.
Key Benefits
Potentially a dual mechanism compound – working via monoamine reuptake inhibition and HDAC inhibition (epigenetic modification).
Quicker acting compound compared to current therapies in the market. Works better than the...
Published: 4/23/2024
Contributor(s): Hyunsuk Shim, Huw Davies, Hyun Min Park, Yoon Hyeun Oum
|